Devonian Health Group Inc. Set to List on NYSE American

QUEBEC, Sept. 11, 2026 /CourierPR/ -- Devonian Health Group Inc., a clinical stage pharmaceutical company based in Quebec, Canada, is set to expand its market presence by listing its common shares and warrants on the NYSE American. The company announced that trading is expected to commence as early as September 16, 2026, under the symbols "DHGR" and "DHGR WS," respectively. This move is part of an underwritten public offering, which will also see the company remain listed on the TSX Venture Exchange (TSXV) under the symbol "GSD."

Devonian Health Group Inc. specializes in the development of drugs for various auto-immune fibroinflammatory diseases, including atopic dermatitis, radiodermatitis, and ulcerative colitis. The company's core strategy involves targeting unmet medical needs with novel therapeutic approaches. Its state-of-the-art extraction facility in Quebec supports its research and development efforts.

The anticipated listing on the NYSE American is a significant milestone for the company, reflecting its growing recognition in the pharmaceutical industry. Devonian Health Group Inc. aims to leverage this new listing to enhance its visibility and access to a broader investor base, thereby potentially accelerating the development and commercialization of its drug candidates.

Devonian Health Group Inc. has been in operation since 2015 and is currently traded on the TSXV and quoted on the OTCQB Venture Market. The company's commitment to advancing treatments for fibroinflammatory autoimmune diseases underscores its potential to make a significant impact in the healthcare sector.

As the company prepares for the listing, it remains focused on its mission to develop innovative therapies that address unmet medical needs. The anticipated listing on the NYSE American is seen as a strategic move to support the company's growth and enhance its ability to attract capital for future research and development initiatives.